Rollprint, packaging products company, announced that the prototype laboratory can help cut time to market by providing information about how packaging will behave in the commercial environment, reported
Astellas has announced that US Direct Court in Washington, DC has denied the Temporary Restraining Order and Preliminary Injunction, which have been requested by Astellas’ North American affiliate
FDA has released its official and final report regarding the agency’s review of allegations made in a July newspaper article concerning mylan’s Morgantown, W.Va., manufacturing facility. The newspaper
Continucare Corporation (Continucare) has expanded its service offerings through the acquisition of Professional Sleep Diagnostics. Continucare said that the company’s sleep service activities will be conducted through its
Acacia Research has announced that its subsidiary, Acacia Patent Acquisition, has acquired rights to a patent for biosensor technology. The patented technology generally relates to biosensors, such as
Amsterdam Molecular Therapeutics (AMT) has reported an increase in operating loss to E9.9m for the six months ended June 30, 2009, from E9.1m for the same period in
Amgen will summarize data from the submitted Biologic License Applications (BLAs) at a meeting with the FDA’s Advisory Committee for Reproductive Health Drugs (ACRHD). BLAs, for denosumab for
Abbott has expanded XIENCE V USA post-approval study, designed to evaluate the safety and effectiveness of the company’s XIENCE V Everolimus Eluting Coronary Stent System in a real-world
Angiotech has received approval to market the Quill SRS Polydioxanone (PDO), Monoderm, Polypropylene and Nylon product lines in Brazil. The Quill SRS product lines include two absorbable sutures
Skystar Bio-Pharmaceutical reports gross profit for the second quarter of $3.3m, up 42% from the second quarter of 2008. Gross margin for the quarter was 52.6%, compared to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.